Compare HUIZ & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HUIZ | RNXT |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 37.4M |
| IPO Year | 2019 | 2021 |
| Metric | HUIZ | RNXT |
|---|---|---|
| Price | $1.70 | $0.92 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $2.30 | ★ $8.00 |
| AVG Volume (30 Days) | 4.0K | ★ 156.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,000.00 |
| Revenue This Year | $22.67 | $2,995.35 |
| Revenue Next Year | $8.55 | $219.61 |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $0.70 |
| 52 Week High | $4.16 | $1.45 |
| Indicator | HUIZ | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 42.50 |
| Support Level | $1.90 | $0.89 |
| Resistance Level | $2.48 | $1.07 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 58.63 | 10.29 |
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.